HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE
-
Upload
mauricio-campos-suarez -
Category
Healthcare
-
view
68 -
download
0
Transcript of HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE
![Page 1: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/1.jpg)
Health Care & Pharmaceutical BusinessKey Challenges & IT value
Mauricio Campos SuarezNovember 2016
![Page 2: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/2.jpg)
Content• Key Challenges• The transformation• IT role
Health Care & Pharmaceutical BusinessKey Challenges & IT value
![Page 3: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/3.jpg)
Pharma Key challengesExternal factors
• Global exponential population growth• Increase in life expectancy• Increase of chronic diseases
![Page 4: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/4.jpg)
Global exponential population
growth
https://www.census.gov/popclock/ UNITED 7Billion Actions
![Page 5: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/5.jpg)
Global increase in
life expectancy
Increase ofchronic diseases
http://www.who.int/kobe_centre/ageing/en/
![Page 6: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/6.jpg)
Estimated Healthcare uti-lization by 2030
< 65 years> 65 years
Polulation > 650%
50%
100%
150%
200%
2030Now
Chronic disease0%
20%40%60%80%
100%120%140%
2030Now
Growth
Conservative, Diabetes prevalence will increase 165% between now and 2050
Source http://www.census.gov/
+ 500 million people
+ 46 million people (only US)
![Page 7: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/7.jpg)
Pharma Key challengesInternal factors
• Patents expiration• Inefficiencies• Pipeline shrink• Internal Complexity/High Cost
![Page 8: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/8.jpg)
New Molec1ule chances: 0,01 % success in 15
years
10 years exclusive commercialization
Key challengesInternal factors: R&D
![Page 9: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/9.jpg)
Top Pharma R&D budget around u$s
150 bln
New medicines registration
New playersBig pharma
Equal to around 50 countries
GDP together
Key challengesInternal factors: R&D
http://unstats.un.org/unsd/snaama/dnllist.asp https://www.ft.com
![Page 10: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/10.jpg)
The Transformation
![Page 11: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/11.jpg)
Reinventing Pharma Business
Drive EfficienciesAlliances Management
Perform
InnovateBusiness Development
Transform
![Page 12: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/12.jpg)
![Page 13: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/13.jpg)
Leverage IT to accelerate the transformation
![Page 14: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/14.jpg)
• Information as a key asset
• Outcome based HealthCare, Predictive Analytics
• “Broadening horizons”• Non-traditional Pharma Players &
Startups partnership
• “It’s all about our patients”
• e-Patient
• “You will not always see the doctor”• Telemedicine & Technologic solution
to reduce HC costs
Business model
development
Add value & build trust
Insights management
Technology Ecosystem
Collaboration
Pharma Transformation: IT Value
![Page 15: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/15.jpg)
Beyond the pill
Shortage of up to 200,000 doctors by 2020 in US only
By 2020 the estimation is to move 40% of health care to the home
Global telemedicine market expected to reach close to USD 48.10 billion in revenue by 2019
![Page 16: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/16.jpg)
E-Patient
ePatients are the individuals who are equipped, enabled, empowered and engaged in their health and health care (HC) decisions. Envisioning HC as an equal partnership between e-patients and HC professionals and systems that support them
e-Patients.net
Digitally enabled solutions are becoming critical to serving both parties’ (Payors, Patients) needs
![Page 17: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/17.jpg)
Influenza epidemicsprediction
• Google prediction (in black) • Actual flu cases (in red) Source Nature.com
+ 90 million people (US) search in Internet their health problems
Big data revolution in healthcare
EXAMPLE
Estimation based on internet searching data
![Page 18: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/18.jpg)
Big data revolution in healthcare
Payors and governments have an ever sharper focus on managing costs while delivering improved patient outcomes, putting an even greater onus on pharma companies to demonstrate the value of their drugs in the real world—not just in randomized controlled trials—if they are to retain market access and premium pricing
![Page 19: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/19.jpg)
New players
EXAMPLEThe big majority of technological companies have a HealthCare division
![Page 20: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/20.jpg)
Open Challenges to Start-ups
EXAMPLES
![Page 21: HEALTH CARE & PHARMACEUTICAL BUSINESS: KEY CHALLENGES & IT VALUE](https://reader036.fdocuments.net/reader036/viewer/2022070519/58eee91e1a28abb24b8b45e7/html5/thumbnails/21.jpg)
More about this at….http://www.globalchange.comhttp://www.gapminder.orghttp://www.silverbook.orghttp://www.census.govhttp://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/the-road-to-digital-success-in-pharmahttps://hbr.org/2013/09/value-based-health-care-is-inevitable-and-thats-good